The P-REVIEW study was a prospective, multicenter, open intervention study, designed to determine whether a multifaceted intervention of educating the prescriber combined with medication review and pharmaceutical visits to the ward by the hospital pharmacist could lead to a reduction in drug-related complications among surgical patients.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Problems due to prescribing errors that lead to potentially preventable morbidity, mortality and costs are common among hospitalized patients.
• Different interventions to minimize these problems such as medication review, medication reconciliation, computerized physician order entry system with clinical decision support, educational programmes and multifaceted approaches have been studied but there is no evidence indicating that these interventions improve clinically relevant outcomes.
WHAT THIS STUDY ADDS
• Introducing a teaching programme for prescribers combined with support of the prescribing physician by the hospital pharmacist on the ward, based on medication reviews in high-risk patients, leads to a clinically relevant benefit for surgical patients.
• Introduction of such a programme does not incur extra costs.
Introduction
Problems due to errors in pharmacotherapy are common among hospitalized patients [2] [3] [4] [5] . Many of these derive from prescribing errors that lead to potentially preventable morbidity, mortality and costs. The majority are caused by pain medication [non-steroidal anti-inflammatory drugs (NSAIDs) and opioids], (combination of) antithrombotics, antibacterial drugs, cardiovascular drugs, and drugs that are renally excreted [2-4, 6, 7] . Especially patients on surgical wards are at risk, due to the need for pain medication and antibiotics, frequent adjustments of antithrombotic regimens and blood and fluid loss [8] . In the case of elderly surgical patients, multiple co-morbidities requiring multiple drugs add even more to the potential drug-related problems [9] . The care for these patients is often provided by junior physicians. These junior doctors do not consider themselves sufficiently trained to prescribe [10] [11] [12] and they are often supervised by surgeons who have no specific expertise with respect to complex pharmacotherapy.
Guidelines have been developed to assist doctors and improve care, but implementation of these guidelines is challenging and adherence is limited, possibly because of frequent rotations of inexperienced physicians on these wards [13, 14] .
Several approaches may be considered to minimize prescription errors. It was shown that implementation of a comprehensive checklist, including medication-related items, can reduce surgical complications and mortality [15] . In addition, computerized physician order entry (CPOE) in combination with a clinical decision support system can support both the physician and the hospital pharmacist. However, some prescription errors may still be missed [16, 17] , while at the same time alert fatigue may arise as the result of irrelevant alerts, increasing the likelihood that important alerts go unnoticed [18, 19] . The inexperienced physician on the ward lacks adequate knowledge to interpret the alerts. In most hospitals, overridden alerts are checked by hospital pharmacists. However, for a comprehensive judgement of the medication of the patient by the hospital pharmacist, detailed knowledge about the clinical situation is needed.
This has led to more active involvement of hospital pharmacists on clinical wards. This approach, however, is time consuming. Despite research that demonstrates the benefits of different clinical pharmacy services [20] [21] [22] , there is only scarce evidence of benefit on clinically relevant outcome measures for patients on general (non-ICU) wards [23] [24] [25] .
Another strategy to reduce prescribing errors aims at educating the prescriber. Although this has been shown to reduce prescribing errors, the effect is not sustained over time [26] . An educational programme could be made more sustainable by combining it with pharmaceutical care visits by the hospital pharmacist to the ward. The educational programme teaches the pharmacological aspects of using high-risk drugs in high-risk patients. The goal of the visits by the hospital pharmacist is to boost the effects of education and to suggest interventions based on a medication review of the patient. By discussing prescribing errors, these medication reviews will also have an educational effect. To reduce the workload of the hospital pharmacist and to improve feasibility of the intervention, patients at risk of drug-related problems are selected based on medication use and clinical features. Guidelines (e.g. on peri-operative anticoagulation policy) are an important part of the educational programme. The visiting hospital pharmacist actively checks and teaches on guideline adherence.
The P-REVIEW study (Pharmacist-led Risk patients medication EValuation to Initiate Event reduction on surgical Wards) was designed to investigate whether such an approach could lead to a reduction of drug-related complications among high-risk surgical patients.
Methods

Study design and setting
The P-REVIEW study was an open intervention study with a before-after design performed in two large general teaching hospitals in the Netherlands (the Isala Hospital in Zwolle, 779 beds, and the Meander Medical Centre in Amersfoort, 600 beds). In total, 12 hospital pharmacists participated in the study. The institutional review boards of the Isala Hospital and the Meander Medical Centre stated that the study was exempt from ethical approval. Patient data were collected and stored in accordance with prevailing privacy regulations.
Study population
All patients who were admitted to the surgical, urological and orthopaedic wards of the two hospitals during a usual care period (1 June 2011-1 December 2011) and an intervention period (1 March 2012-1 September 2012) were included in the study. Both periods were of six months duration, with a three-month period in between, during which the intervention was introduced. Patients were followed up until discharge. Patients could be included more than once, in case of readmission. Day care patients were excluded.
Usual care period
During the usual care period, the normal procedures of medication surveillance and communication between hospital pharmacists and physicians were maintained. A computerized physician order entry (CPOE) system with clinical decision support (CDS) was applied in both hospitals. There was no orthogeriatric service at the time of the study.
Briefly, hospital pharmacists checked medication of all patients on a daily basis with the aid of computer-generated alerts based on a national database ('G-standard'; www.z-index.nl). Hospital pharmacists could warn the physician by telephone or send a factsheet to the ward. In both hospitals, pharmacists were supported by a set of computerized 'clinical rules' to screen for specific prescription errors. These clinical rules combine clinical patient data (like renal function and electrolyte abnormalities) with the medication to judge, for example, whether dose adjustments should be made in case of renal insufficiency or if gastric protection should be added to an NSAID [27] .
Intervention period
During the intervention, a combination of an educational programme and medication counselling for prescribers dealing with high-risk patients on the wards took place, in addition to the procedures described above.
An educational programme covering pain management, antithrombotics, fluid and electrolyte management, prescription in the case of renal insufficiency, application of radiographic contrast agents and surgical antibiotic prophylaxis was developed. National and local hospital guidelines relating to these subjects were also included. The programme consisted of two parts of approximately 2 hours each. All prescribers on the participating wards attended the course.
Hospital pharmacists were trained to perform medication safety consultations (MSC), combining a medication review and a visit to the ward. A computerized screening method identified high-risk patients. The screening method was based on recent literature on prescription errors and targeted patients at risk for potentially preventable, drug-related problems [2, 28] (Appendix 1). Hospital pharmacists performed the medication review by using a checklist, in order to establish uniformity (Appendix 2). The review was performed weekly and discussed with the prescriber on the ward.
Study endpoints
The primary outcome of this study was the proportion of patients with one or more potentially preventable, clinically relevant, drug-related problems. Clinically relevant problems included death, temporary or sustained disability, increased length of hospital stay or readmission within 30 days. Secondary endpoints were characterization of drug-related problems and costs that were incurred by the hospital as a result of running the programme.
Data collection
Collected data included patient characteristics, laboratory and medication data, as well as admission mutations, medical correspondence and medical interventions. Data regarding radiology, microbiology, blood transfusion and information about medical incidents were also collected.
A semi-automatic trigger instrument using electronic patient records was used to identify possible drug-related problems based on these data (Appendix 3). It consisted of a comprehensive set of phenomena such as (change in) laboratory results, medication use, clinical interventions (e.g. gastroscopy), radiology examinations, consultations of other specialists, transfer to the intensive care unit, readmission within 30 days, and death [2, [29] [30] [31] [32] . Assessment of triggers and filling out of the case report was performed at least two weeks after discharge or death of the patient to avoid influencing daily practice. The major part of the data collection and the identification of possible cases with a clinically relevant, drug-related problem based on the trigger list was performed automatically, using a validated multisource Microsoft Access database (Microsoft version 2003). In addition, some of the data were collected manually and edited by a trained research assistant in the hospital using a predefined protocol (Appendix 3).
Recommendations on pharmacotherapy, based on the MSC, performed by the hospital pharmacist during the invention period, were documented in the database.
On the fifth month of both periods, pharmacy assistants and hospital pharmacists registered the time they spent on activities such as checking prescribed medication and interventions performed. In the intervention period they also registered time spent on activities such as medication review of high-risk patients and medication safety consultation on the ward. They also made an estimate of the time spent by the prescribing physician to follow up the advice. Time spent on the educational programme by hospital pharmacists and prescribing physicians of the participating wards during the intervention was also registered. Costs were calculated by multiplying the time spent on the study-related activities by salary expenditures of healthcare providers, obtained from the collective labour agreement of Dutch hospitals (www. nvz-ziekenhuizen.nl).
All case record forms (CRF) of the patients with one or more triggers were assessed by three teams of two experts. Every team consisted of a hospital pharmacist and a hospital-based physician. These teams had no relation to the hospitals where the study was performed.
The experts independently assessed whether there was a clinically relevant, drug-related problem that had led to death, temporary or permanent disability, increased length of hospital stay or readmission within 30 days. Prescription errors leading to drug-related problems were identified in a broad perspective, including identification and prevention of possible adverse drug reactions, drug interactions, protocol adherence and omission of medication. To classify seriousness, the National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP) index was used. Categories E to I of this index were considered to be clinically relevant [33] . The causality between prescription error and the drug-related problem was assessed using the algorithm by Kramer et al. [34] . The potential preventability was assessed using the algorithm according to Schumock et al., modified by Lau et al. [35, 36] . The experts were blinded to the period (usual care or intervention) during which the problem occurred.
If there was no agreement between the experts of a team about the occurrence of a drug-related problem or about the clinical relevance, the causality or the preventability of the problem, consensus was achieved in consensus meetings with the expert teams.
Sample size and data analysis
On the basis of the available literature, we estimated that the proportion of clinically relevant, potentially preventable, drug-related problems among surgical patients would be 0.7% [37] . Our study was powered to detect a reduction of this proportion by at least 50%. A two-group, chi-square test with a 0.05 one-sided significance level will have 80% power to detect such difference when the sample size per group is 5300. Baseline characteristics were presented as means and standard deviation or percentages for continuous or dichotomous outcomes, respectively. Differences between groups were tested on statistically significant difference with either an independent t-test or a chi-square test depending on type of data.
The difference in proportion of clinically relevant drug-related complications was expressed in relative risk with 95% confidence interval. In addition, the average number of high-risk patients needed to review in order to prevent one clinically relevant drug-related complication was calculated (1/ARR). As a secondary analysis, the relative risk (RR) of clinically relevant drug-related complications between the two periods was corrected for confounders using binominal logistic regression. Age, gender, department where the admission took place and whether or not the admission was planned were considered as confounders and included in the regression analysis as fixed factors. Costs were compared between the two periods with a student's t-test. Statistical analyses were performed using SPSS Statistics version 21.
Results
In the usual care period of the study, 6780 admissions (5940 patients) and in the intervention period 6484 admissions (5711 patients) were included. Table 1 details the characteristics of these admissions.
A significantly lower proportion of admissions with one or more clinically relevant, potentially preventable, drugrelated problems occurred in the intervention period [1.1% (73/6484)] compared to the usual care period of the study [1.6% (106/6780)] (P = 0.029). The RR was 0.72 (95% CI: 0.53-0.97). After correction for potential confounders (age, gender, department, planned admission) the adjusted RR was 0.74 (95% CI: 0.54-1.00) ( Table 1) .
When the included patients were divided into the predefined risk classes, the primary end point changed from 3.7% (89/2392) to 2.8% (61/2126) in high-risk patients; RR 0.77 (0.55-1.06); and from 0.4% (17/4388) to 0.3% (12/ 4358) in low risk patients; RR 0.71 (0.34-1.49). The average number of high-risk patients that needed to be reviewed in order to prevent one clinically relevant drug-related problem was 111 (100/0.9). Table 2 shows a comparison of intervention-related characteristics. There was no difference in the number of medications the first day after admission. However, there was a Table 2 Comparison of intervention-related characteristics
Usual care period (n = 6780) Intervention period (n = 6484) P-value
Mean no. of medications the first day after admission, ± SD 6.65 ± 5.54 6.57 ± 5.65 0.397
Medication the first day after admission, n (%) a Number of admissions during which a MDRD of the patient was measured LMWH = low molecular weight heparin; NSAIDs = non-steroidal anti-inflammatory drugs; RAS = renin angiotensin system (small) decrease in the percentage of admitted patients using specific medication groups. In some groups (heparin/LMWH, diuretics, beta blockers, opioids) this reduction was statistically significant. In addition, length of hospital stay and the number of patients with renal insufficiency decreased after the intervention. Table 3 describes the characteristics of the patients with an event. The patients who had an event were older and used more drugs at the first day after admission. The mean length of hospital stay of these patients was slightly shorter after the intervention than in the usual care period, but significantly longer than the mean length of hospital stay of the total of patients. The mean time until the occurrence of the event showed no difference between the two periods. Table 4 describes the types of events in patients with a drug-related problem. Several types of events occurred less frequently during the intervention period, especially haemorrhage, thrombosis and central nervous system events (mainly delirium). Table 5 shows the costs of study-related activities during the usual care period and the intervention period of the study. During the intervention, the costs per admission were higher for hospital pharmacists because they performed MSC and ward visits. The costs of pharmacy assistants, however, were lower. Costs of the training of pharmacists and prescribers were assessed and expressed as extra costs per admission. Taken together, mean total costs were €6.04 (95% CI: 5.82-6.26) per admission in the usual care period. These were not statistically significantly different from €6.18 (95% CI: 6.06-6.30) per admission in the intervention period.
Discussion
The P-REVIEW study shows that a teaching programme for prescribers, combined with performing medication reviews in patients at risk for drug-related problems, and weekly visits of a hospital pharmacist to the ward significantly reduces clinically relevant, potentially preventable, drug-related Table 3 Characteristics of patients with an event Mean no. of medications the first day after admission, ± SD 11.1 ± 4.9 12.4 ± 5.1
Mean length of stay, days ± SD 14.2 ± 10.4 13.1 ± 9.7
Mean duration until occurrence of event (including events, leading to readmission), days ± SEM 6.7 ± 0.7 6.8 ± 0.8 Table 4 Clinically relevant, potentially preventable, drug-related problems due to prescription errors: type of events Renal insufficiency, hydration or electrolyte related event (diuretics, NSAID, RAAS inhibitors)
14
Drug intoxication in renal insufficiency (unadjusted therapy) 4 1
Central nervous systems events mainly delirium (tramadol, anticholinergic therapy) 48 20 Faecal impaction (opiates) 11 9
Hypoventilation (opiates) 0 2
a These drug-related problems occurred in 102 patients in the control period and 69 patients in the intervention period. b Variable drug-related problems, for instance Addison crisis because of omission of corticosteroids; prescribing salbutamol to a patient, with a known allergy to salbutamol; lithium intoxication because of drug-drug interaction; pulmonary oedema, provoked by naproxen.
Education of prescribers improves patient care on surgical wards problems in patients admitted to surgical wards. The results reveal a significantly lower proportion of admissions with one or more of these problems in the intervention period.
Costs incurred by the hospitals did not increase during the intervention period as the result of time spent on education, medication review and ward visits by hospital pharmacists. P-REVIEW is a study with clinically relevant outcome measures in a very large patient cohort. Different interventions to minimize medication errors such as medication review, medication reconciliation, computerized physician order entry system with clinical decision support, educational programmes and multifaceted approaches have been studied before. These studies were generally insufficiently powered and focused on surrogate endpoints such as prescription errors, medication discrepancies or prevention of potential harm. The studies showed substantial heterogeneity in these outcomes.
Some studies indicate that these interventions improve patient management or clinically relevant outcomes [20] . However, most studies were methodologically weak, as they used non-blinded designs and lacked robust data collection methods [16, [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] .
In two smaller studies it was shown that educational programmes reduced prescription errors in the ICU and among hospitalized elderly, although they failed to show an effect on clinically relevant outcomes [46, 48] . When education was incorporated in a multifaceted approach, hospital anticoagulation management improved, which led to reduction of venous thromboembolism (VTE) and costs [49] . Reduction of VTE was also found after implementation of a computerized clinical decision support system [50] . Decision support plus validation by a pharmacist led to more efficient pharmaceutical care on the ICU and reduction of potential prescribing errors on clinical wards in a tertiary referral hospital, but did not show improvement on clinically relevant patient outcomes [51, 52] . The SUREPILL study, which evaluated a protocolled, ward-based pharmacy method compared with standard pharmaceutical care in surgical patients, showed no reduction in medication-related harm or changes in clinical outcomes [25] .
The P-REVIEW study has several strengths. The intervention combines two strategies which have been employed separately in the past: structured medication reviews followed by visits to the ward by the hospital pharmacist and education of prescribers. Both interventions have been found to be effective in reducing drug-related problems, but the effect on clinically relevant endpoints was still unknown. Education of prescribers has been found to have only a transient effect on the frequency of prescribing errors [26] . In our study we aimed to boost this effect by the weekly visits of the hospital pharmacist as a form of workplace-based pharmacotherapy education.
Furthermore, we used risk stratification to make the efforts of the hospital pharmacist more efficient. As one of the purposes of the weekly medication review and the visits to the ward was education of prescribers, we reasoned that we did not need to address all possible prescription errors. We showed that low-risk patients (without medication reviews) may also benefit from the effect of the intervention.
As the primary outcome, we studied clinically relevant patient outcome measures (death, temporary or permanent disability, increased hospital stay or readmission) in a very large patient cohort. Prescription errors, leading to these clinically relevant drug-related problems, were identified in a broad perspective, including possible adverse drug reactions, drug interactions, guideline non-adherence and omission of medication.
The intervention was performed by healthcare providers already active in the hospital, so implementation was relatively straightforward. The study was performed in two large teaching hospitals that are representative of the majority of hospitals in the Netherlands.
Besides these strengths, the study also has a number of limitations. The study had a before-after design. Therefore, it is impossible to ascertain whether differences in characteristics, such as the use of certain drugs, are caused by the intervention or should be ascribed to differences between the groups. We considered a randomized controlled design impossible, as both the educational programme and the visit by the pharmacist will contaminate usual care as residents and other healthcare providers learn from this intervention. By blinding all case record forms with respect to the study period before assessment by the experts and by correcting for confounders, the probability of bias was minimized.
Next, the study was performed in two hospitals in the Netherlands possibly limiting the external validity of the study. The role of the hospital pharmacist on the ward can be different in other countries. This study used a trigger instrument to identify clinically relevant, medication-related events, based on different trigger instruments described in the literature. However, this has not been formally validated and therefore some events might have been missed. Nevertheless, as events will have been missed both before and after, this may only limit the power of the study, without biasing the outcome.
The cost analysis shows that this intervention does not lead to extra costs. However, in the analysis only time spent by healthcare workers was taken into account. Possible effects on medication use and laboratory tests were not included, but the costs of the drug-related complications were not calculated either.
This study shows that introducing a teaching programme for prescribers, combined with performing medication reviews in high-risk patients and weekly visits of a hospital pharmacist to the surgical ward, contributes to patient safety and should be implemented in all hospitals. The implementation of these activities is relatively easy and can be performed by healthcare providers already active in the hospital. The time and effort needed from the hospital pharmacist to perform MSC and ward visits and to train prescribers are compensated by less time consumed by pharmacy assistants, probably due to less need for interventional activities.
Although on first sight reducing clinically relevant drugrelated errors from 1.6 to 1.1% seems not especially impressive, one has to take into account that each year in the Netherlands 4 million hospital admissions take place. This means that thousands of patients would benefit from nationwide implementation of this intervention.
Further investigation should address improvement of the identification of high-risk patients. We intend to perform a post-hoc analysis of the P-REVIEW database to identify more specific predictive factors for patients at risk of clinically relevant preventable medication-related adverse events. Being able to more accurately predict which patients are at risk of a drug-related complication during hospital admission would improve the efficiency of interventions. The method used for risk identification could be different between hospital wards of different medical specialties. In addition, we intend to investigate whether the implementation of education of prescribers and performing medication reviews also has an effect on relevant patient outcomes in non-surgical medical specialties such as internal medicine, neurology or psychiatry.
In summary, this large study shows that education and support of the prescribing physician by the hospital pharmacist with respect to high-risk patients in surgical departments leads to a significant clinically relevant benefit for patients. This study also shows this helps reduce clinically relevant medicationrelated problems without generating additional costs.
Checklist for performing medication review on surgical wards
The checklist below is not meant to be complete, but is meant to support the hospital pharmacist in performing medication review and to establish uniformity. 
